source
- Cloudbreak Pharma’s Phase 3 Eye Drop Shows Significant Benefit in Pterygium TrialCloudbreak Pharma reported that its phase 3 trial of CBT-001, a multi‑kinase inhibitor eye drop for pterygium, met both co‑primary endpoints. The study compared two doses of CBT-001 given twice da…
- AAFP chief urges Congress to add oversight to CDC vaccine advisory panelShawn Martin, CEO of the American Academy of Family Physicians, said the CDC’s Advisory Committee on Immunization Practices (ACIP) has faced more than a year of turmoil. He is urging Congress to e…